Autologous myelin basic protein-reactive T cells

Autologous MBP-reactive T cells refer to a personalized immunotherapy approach in which a patient's own (autologous) T cells that are reactive to myelin basic protein (MBP) are isolated, expanded, and then attenuated or inactivated before being reintroduced as a therapeutic vaccine. This strategy is primarily investigated for the treatment of multiple sclerosis (MS), an autoimmune disease characterized by immune-mediated damage to central nervous system myelin. The mechanism of action involves using these attenuated autoreactive T cells as a "T cell vaccine" to induce regulatory immune responses that target and deplete pathogenic autoreactive clones or promote regulatory networks that suppress autoimmunity. Clinical studies have shown this approach can reduce circulating pathogenic MBP-reactive T cell populations and may enhance regulatory CD4+CD25+Foxp3+ responses[1][2][5]. The therapy is experimental and not commercially available; it is typically developed on a per-patient basis within academic research settings.

Other names

autologous myelin basic protein-reactive T cellsautologous MBP-specific T cell vaccineinactivated autologous MBP-reactive T cell clones